Evofem Biosciences AI Stock Analysis
Want to see EVFM full AI Analyst Report?
Evofem Biosciences (EVFM) AI Stock Analysis
Evofem Biosciences
(Other OTC:EVFM)
EVFM scores near the bottom of the range, driven overwhelmingly by an insolvent balance sheet — negative shareholders' equity of -$78.8 million and $70.4 million of debt against just $7.3 million of assets — combined with a 27% TTM revenue decline and a return to operating and net losses. Valuation offers no support, with a negative P/E, no dividend, and a $0.01 share price reflecting distress. Partially offsetting these risks are a sharply reduced cost structure with cash burn now near breakeven, healthy ~70% gross margins, and a new second-source PHEXX manufacturing agreement that could improve unit economics and support global expansion. Overall, this remains a highly speculative situation where operational progress is overshadowed by capital structure risk.
Evofem Biosciences (EVFM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $569.88K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 0.32
- Revenue Growth
- -0.03%
- EPS Growth
- -88.76%
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Evofem Biosciences Business Overview & Revenue Model
Company Description
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phex...
Evofem Biosciences Financial Statement Overview
Summary
Financials are distressed. The balance sheet is the core problem: shareholders' equity of -$78.8 million, $70.4 million of debt against only $7.3 million of total assets, signaling severe solvency risk and dependence on refinancing or dilutive raises. The income statement has improved dramatically from prior multi-hundred-million-dollar losses and briefly turned profitable in fiscal 2025, but TTM revenue fell 27.4% to $13.1 million and results swung back to a $3.0 million operating loss and $12.9 million net loss. Cash burn has been cut to near breakeven (-$0.6 million TTM free cash flow), the one clear bright spot, yet operations have never produced positive cash and liquidity cushion is minimal.
Income Statement
27NegativeBalance Sheet
7Very NegativeCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.72M | 20.18M | 19.36M | 18.22M | 16.84M | 8.24M |
| Gross Profit | 12.94M | 15.07M | 15.53M | 11.71M | 12.42M | 4.19M |
| EBITDA | -2.66M | 2.06M | -6.92M | -16.07M | -82.08M | -165.78M |
| Net Income | -12.73M | 391.00K | -8.86M | 52.98M | -76.70M | -205.19M |
Balance Sheet | ||||||
| Total Assets | 7.26M | 20.27M | 23.79M | 10.55M | 25.16M | 42.51M |
| Cash, Cash Equivalents and Short-Term Investments | 317.00K | 578.00K | 741.00K | 580.00K | 2.77M | 7.73M |
| Total Debt | 70.39M | 54.55M | 45.97M | 43.37M | 71.13M | 115.68M |
| Total Liabilities | 86.02M | 89.71M | 95.05M | 77.06M | 96.96M | 142.09M |
| Stockholders Equity | -78.76M | -69.44M | -71.26M | -66.51M | -71.80M | -99.58M |
Cash Flow | ||||||
| Free Cash Flow | -599.00K | -2.00M | -3.90M | -8.97M | -70.75M | -149.61M |
| Operating Cash Flow | -594.00K | -1.99M | -3.88M | -8.97M | -70.41M | -146.67M |
| Investing Cash Flow | -5,000 | -62.00K | -569.00K | -4,000 | -341.00K | -2.69M |
| Financing Cash Flow | 76.00K | 1.89M | 4.62M | 4.78M | 61.94M | 90.69M |
Evofem Biosciences Risk Analysis
Evofem Biosciences disclosed 87 risk factors in its most recent earnings report. Evofem Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksEvofem Biosciences Peers Comparison
Overall Rating
PTN46Neutral
LPCN45Neutral
DARE44Neutral
EVFM40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $9.55M | -0.47 | -235.46% | ― | -46.89% | 55.46% | |
| 45Neutral | $17.72M | -1.19 | -46.52% | ― | -13.37% | -33.44% | |
| 44Neutral | $8.44M | -0.60 | -789.97% | ― | ― | ― | |
| 40Underperform | $569.88K | -0.06 | 16.78% | ― | -0.03% | -88.76% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EVFM | Evofem Biosciences, Inc. | 0.01 | 0.00 | 0.00% | |
| PTN | Palatin Technologies, Inc. | 5.36 | -9.13 | -63.01% | |
| DARE | Daré Bioscience | 0.43 | -1.20 | -73.68% | |
| LPCN | Lipocine Inc | 1.60 | -1.55 | -49.21% |
Evofem Biosciences Corporate Events
Evofem amends key convertible note financing terms
NeutralOn October 9, 2026, Evofem Biosciences, Inc. and Adjuvant Global Health Technology Fund entered into a fifth amendment to their October 14, 2020 Securities Purchase Agreement governing certain convertible promissory notes. The amendment extends and c...
Evofem Expands PHEXX Manufacturing Capacity for Global Growth
PositiveOn September 17, 2026, Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical entities in Hong Kong and Guangzhou to add them as a producer and supplier of PHEXX, its hormone-free contraceptive gel. The mov...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
